Drugs Made In America Acquisition Corp. Rights
NASDAQ: DMAAR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Financial Services
- Industry
- Shell Companies
- CEO
- Roger Bendelac
- Employees
- 2
- Headquarters
- Fort Lauderdale, United States
- IPO year
- 2026
- Market cap
- $359.1M
- Website
- https://dmaacorp.com
Loading DMAAR…
Loading profile data…Frequently asked questions about DMAAR
What does Drugs Made In America Acquisition Corp. Rights (DMAAR) do?
Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company (SPAC), established with the primary objective of identifying and acquiring one or more active businesses or their assets. The company plans to achieve these acquisitions through various transactional structures, including mergers, exchanges of equity shares...
Where does DMAAR trade?
Drugs Made In America Acquisition Corp. Rights (DMAAR) trades on the NASDAQ Global Select.
What sector is DMAAR in?
Drugs Made In America Acquisition Corp. Rights (DMAAR) operates in the Financial Services sector, specifically in the Shell Companies industry.
Who is the CEO of Drugs Made In America Acquisition Corp. Rights?
Roger Bendelac is the chief executive officer of Drugs Made In America Acquisition Corp. Rights (DMAAR).
Where is Drugs Made In America Acquisition Corp. Rights headquartered?
Drugs Made In America Acquisition Corp. Rights is headquartered in United States.
Does DMAAR pay a dividend?
Drugs Made In America Acquisition Corp. Rights (DMAAR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DMAAR go public?
Drugs Made In America Acquisition Corp. Rights (DMAAR) completed its initial public offering in 2026.